BAI Announces 2022 Global Innovation Award Finalists
15.11.2022 22:40:00 EET | Business Wire | Press release
BAI announced the finalists for the 12th Annual BAI Global Innovation Awards, the financial services industry’s leading innovation honor, celebrating organizational achievements. These 27 global trailblazers have successfully designed and delivered innovations that positively improved customer relationships, fostered organizational changes and served their communities. In addition to innovations related to retail and commercial products, digital transformation, community, and organization processes, the finalists represent current themes related to fraud and security, HR and talent development, diversity and inclusion, and ESG.
The 2022 BAI Global Innovation Award finalists are:
Banco Popular (Puerto Rico): Talent Lab & Skills Accelerator
Bank of America (USA): Bank of America Security Center
BankiFi (USA): Open Banking API and Embedded Banking Platform for Businesses
BMO (USA): True Name
DenizBank (Turkey): Technology and Start-up Loans in Agriculture
Dreams Technology (United Kingdom): Dreams ESG Innovation
Fifth Third Bank (USA): Customer Recommendation Engine
FNB (South Africa): FNB Connect
Fonbulucu (Turkey): Fully Integrated Investment Ecosystem
Growsari (Philippines): GROWSARI.com - Powering the Digital Economy of the Philippines
JUMO (South Africa): Core & Unify
Kolleno (United Kingdom): Kolleno AR Platform
Money Management International, Inc (USA): Project Porchlight by MMI
MVB Bank (USA): Onboarding Fintechs Better, Faster, Stronger…the Victor (ad)Vantage
Oportun (USA): Digit by Oportun
OppZo (USA): Democratizing Access to Affordable Working Capital Loans
Payten Technology Inc. (Turkey): Paratika Crowdfunding e-Payment Project
Quilo (USA): Fully Digital Real-Time Syndication Platform
SoLo Funds (USA): SoLo Community Finance Platform
Standard Bank (South Africa): Trader Direct
Standard Bank (South Africa): OneFarm Share
Themis (USA): Making Compliance Easy and Reliable for Banks and Fintechs
Theta Lake (USA): Utilizing AI to Scale Data Security, Risk Detection and Compliance Supervision
TIAA (USA): TIAA Phone Authentication Risk Management (PARM)
Umoja Labs (USA): Building Payment Rails to Enable Universal Access to Affordable Digital Financial Services
Union Bank of India (India): Union Prerna
Yabx Technologies (Netherlands): Simplifying Financial Access, Control and Choice to the Underbanked
Zilch (United Kingdom): Zilch Technology: Financial Services Technology Innovation
“These 27 companies reflect how financial services leaders are bringing original and creative solutions to positively impact their business, customers and other stakeholders,” said Amy Radin, financial services innovation executive, award-winning author, and lead judge of the 2022 BAI Global Innovation Awards.
The winners will be announced in December 2022. To learn more please visit BAI Global Innovation Awards.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006381/en/
Contact information
MEDIA CONTACT:
Kendall Carwile
William Mills Agency
678-781-7224
kendall@williammills.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom